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Abstract
Background: Alternative splicing is a ubiquitous post-transcriptional regulation mechanism in most eukaryotic genes.
Aberrant splicing isoforms and abnormal isoform ratios can contribute to cancer development. Kinase genes are key
regulators of multiple cellular processes. Many kinases are found to be oncogenic and have been intensively investigated
in the study of cancer and drugs. RNA-Seq provides a powerful technology for genome-wide study of alternative splicing
in cancer besides the conventional gene expression profiling. But this potential has not been fully demonstrated yet.
Methods: We characterized the transcriptome profile of prostate cancer using RNA-Seq data from viewpoints of both
differential expression and differential splicing, with an emphasis on kinase genes and their splicing variations. We built
a pipeline to conduct differential expression and differential splicing analysis, followed by functional enrichment analysis.
We performed kinase domain analysis to identify the functionally important candidate kinase gene in prostate cancer,
and calculated the expression levels of isoforms to explore the function of isoform switching of kinase genes in prostate
cancer.
Results: We identified distinct gene groups from differential expression and splicing analyses, which suggested that
alternative splicing adds another level to gene expression regulation. Enriched GO terms of differentially expressed and
spliced kinase genes were found to play different roles in regulation of cellular metabolism. Function analysis
on differentially spliced kinase genes showed that differentially spliced exons of these genes are significantly
enriched in protein kinase domains. Among them, we found that gene CDK5 has isoform switching between
prostate cancer and benign tissues, which may affect cancer development by changing androgen receptor
(AR) phosphorylation. The observation was validated in another RNA-Seq dataset of prostate cancer cell lines.
Conclusions: Our work characterized the expression and splicing profiles of kinase genes in prostate cancer and
proposed a hypothetical model on isoform switching of CDK5 and AR phosphorylation in prostate cancer. These
findings bring new understanding to the role of alternatively spliced kinases in prostate cancer and also demonstrate
the use of RNA-Seq data in studying alternative splicing in cancer.
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Background
Alternative splicing is an important post-transcriptional
regulation mechanism through which one gene can pro-
duce multiple isoforms. It is ubiquitous in human cells,
and about 95% of human multi-exon genes undergo this
process [1]. The multiple protein isoforms generated
with this mechanism play critical roles in diverse cellular
processes such as cell cycle control, differentiation and
cell signaling, etc. [2]. Aberrant alternative splicing has
been reported to be highly relevant to many human
diseases including cancer. Many cancer-related genes
undergo alternative splicing and cancer-specific alterna-
tive splicing events have been found to contribute to
carcinogenesis [3]. RNA-Seq technology and bioinfor-
matics methods have provided great opportunities for
studying alternative splicing in cancers [4].
Prostate cancer is a major type of cancer in men. Normal
prostate tissue development needs steady activity of andro-
gens with androgen receptors (AR). AR is an important
transcription factor that regulates the expression of many
downstream genes. AR transcriptional activity, i.e., its
regulatory activity on downstream genes, is modulated
by interactions of AR and co-regulators. Some kinase-
related signal transduction pathways can regulate AR
transcriptional activities via phosphorylation of AR and
AR co-regulators, which may be a main mechanism to
maintain AR transcriptional activity in AR-negative
prostate cancer cells [5]. Protein kinases are one of the
largest gene families in human and they constitute ~
1.7% of human genes [6]. Mutations and dysregulation
of protein kinases have been found to be causal for
some human diseases, and especially for cancer. Efforts
have been made to target oncogenic kinases by devel-
oping inhibitors for disease therapy [7]. Merkin et al.
revealed that a large percentage of alternative splicing
events often contribute to alterations in protein phosphor-
ylation and kinase signaling [8]. It has been observed that
some aberrant splicing events can modify kinase activities
by truncating the kinase domain or fine-tuning the binding
specificity to functional partners [9].
Many efforts have been devoted to the study of kinases
that are deregulated in cancer and may serve as potential
targets for cancer treatment. Differential expression of
kinase genes in prostate cancer has been studied with
RT-PCR [10] and microarrays [11], but the alternative
splicing of these genes have not been systematically
studied in prostate cancer. In this study, using an RNA-
Seq dataset published by Kannan et al. [12], we charac-
terized the transcriptome profile in prostate cancer on
both differential expression and differential splicing, with
emphases on kinase genes and their splicing isoforms.
We profiled genes that are differentially expressed (DE)
and differentially spliced (DS) between prostate cancer
and benign tissues, and used GO and KEGG pathway
enrichment analyses to reveal their distinct functions in
prostate cancer. We studied the kinases among the
detected genes and identified kinases that may have
function alterations caused by differential splicing through
protein domain analysis. Among them, CDK5 was
detected to undergo isoform switching between prostate
cancer and benign tissues, which suggests an important
regulatory role of CDK5 alternative splicing on AR phos-
phorylation in prostate cancer. The result was validated
on another RNA-Seq dataset of prostate cancer cell lines
[13], and also has implications regarding the difference
between androgen-dependent and androgen-independent
cancer progressions.
Methods
To characterize the transcriptome profile in prostate
cancer, we analyzed an RNA-Seq dataset by Kannan et al.
[12] using the strategy we discussed in [4]. The pipeline of
the analysis is shown in Fig. 1. The RNA-Seq data of 20
prostate cancer and ten matched benign tissue samples were
downloaded from NCBI SRA database (accession number
SRP002628). Another prostate cancer cell line dataset was
obtained for validation from SRA (accession number
SRP004637), which contain 58 RNA-Seq samples from 21
prostate cancer cell lines [13]. The short sequencing reads
were first remapped to human reference genome using
TopHat (version 1.4.1) [14]. Uniquely mapped reads with no
more than two mismatches were kept for downstream
analyses.
Identification of DE genes was conducted using DEGseq
(version 1.2.2) [15]. Genes were reported as differentially
expressed for downstream analysis at two significance
cut-offs: p-value < 0.05 and FDR < 1%.
We used DSGseq [16] and DEXSeq (version 1.6.0) [17]
to detect DS genes between the two groups. DSGseq
uses negative-binomial distribution to model read counts
on exons and defines a NB-statistic to detect differences
in the usage of exons between two groups. The cut-off
of NB_stat = 2 was used, corresponding to a moderate
stringency [16]. DEXSeq also detects differential splicing
in an exon-centric manner with p-values reported for
differential usage of each exon. We chose adjusted
p-value < 0.05 as cut-off for DS exons. The consensus
results of the two methods were reported as DS exons
and DS genes.
We used GOseq (version 1.10.0) [18] to identify Gene
Ontology (GO) terms which are over-represented in the
detected genes. GOseq has special designs in its statis-
tical test for avoiding possible selection bias toward long
and highly expressed genes. GO terms were considered
as statistically significant with false discovery rate (FDR)
< 0.05. We mapped the DE and DS kinase genes to
KEGG pathways and used the DAVID tool [19] to study
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Fig. 1 Overview of data analysis pipeline. After mapping the RNA-seq reads to the reference genome, differential expression (DE) analysis and
differential splicing (DS) analysis were applied on the estimated gene and exon expression values, using DEGseq [15] and DSGseq [16] plus
DEXseq [17], respectively. Enrichment analysis on GO terms and KEGG pathways were applied on the obtained lists of DE genes and DS genes to
get the overall picture of functions of the DE and DS genes. Protein domain analysis was applied on the DS exons of the kinase genes. Isoform
expressions were estimated using NURD [20] to quantitatively study the isoform proportions of candidate genes. An additional dataset was used
to validate the observations
Feng et al. BMC Genomics 2018, 19(Suppl 6):564 Page 155 of 193
pathways they are enriched in. Pathways with p-value <
0.05 were declared significant.
Pfam domain search was carried out to analyze the
protein kinase activity of the alternative splicing exons
in the DS kinase genes. We built a background set by
extracting all alternative exons of 518 kinase genes
according to the annotation of hg18 downloaded from
UCSC Genome Browser. DNA regions of both the DS
exons and the background set were translated into pep-
tides in six-frame manner using sequence translation
tool “EMBOSS Transeq”. The peptides sequences were
searched against Pfam database for matching domains
with the default cut-off value of E-value = 1.0. Fisher’s
Exact Test was performed to compare the kinase domain
hits of DS kinase exons and background exons (All the
customized scripts are available upon request).
The software NURD (version 1.1.0) [20] was used to
study the isoform expression levels of DS genes. It uses
nonparametric models to deal with possible position-re-
lated biases in RNA-Seq data and estimates the isoform
expression by maximizing a likelihood function.
Results
Differential expression analysis reveals gene signatures of
prostate cancer
Comparing prostate cancer and benign tissue samples
with DEGseq, we identified 3093 genes as differentially
expressed with p-value < 0.05. Among them, 528 genes are
differentially expressed with FDR < 1% (Additional file 1).
Focusing on kinase genes, we found 62 DE kinase genes at
p-value < 0.05 and 16 DE kinase genes at FDR < 1%
(Additional file 2).
We listed the top 10 up-regulated genes and top 10
down-regulated genes and their function annotations in
Table 1. Most of the top genes have been reported to be
related with prostate cancer. The top up-regulated gene in
prostate cancer is phospholipase A2 group (PLA2G2A),
an important enzyme in inflammatory processes. The
expression of PLA2G2A has been reported significantly
increased in prostate cancer comparing to benign tissue,
and it might serve as a prognostic maker for prostate
cancer [21]. The second up-regulated gene orosomucoid 1
(ORM1) is an AR-activated gene and involved in AR path-
way [22]. Ayla et al. found that ORM1 was differentially
expressed between non-recurrent primary and metastatic
prostate cancer and was involved in cancer metabolism
and immune response pathways [23]. Notably, the fifth
up-regulated gene antigen 3 (PCA3) is a non-protein
coding gene. PCA3 is prostate-specific and has been shown
highly expressed in prostate cancer, and has been identified
as a genetic marker for prostate cancer diagnosis [24].
The most down-regulated gene in prostate cancer is
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase,
antitrypsin) member 3(SERPINA3), whose protein product
Alpha 1 antichymotrypsin (ACT) is associated with
increased risk of prostate cancer [25]. The second
down-regulated gene lactotransferrin (LTF) is a mem-
ber of transferrin family and its protein product is a
major iron-binding protein. One study identified LTF as
the most significantly down-regulated gene in prostate
cancer cells and proved that LTF protein can inhibit
the growth of prostate cancer cells [26]. Its down regu-
lation might be involved in prostate cancer progression
[26]. Another gene that deserves highlight is superoxide
dismutase 2(SOD2). It encodes a mitochondrial enzyme
that can protect cell from oxidative damage, and has
been known as a tumor suppressor gene in human
prostate cancer [27]. Increased expression of SOD2 can
result in the suppression of prostate cancer cell growth
by mediating the senescence-associated tumor suppres-
sion with insulin-like growth factor binding protein re-
lated protein-1 (IGFBP-rP1) [27]. The down regulation
of SOD2 may help promote the cancer progression.
Most differentially spliced genes in prostate cancer do
not show differential total expression
Besides differential expression analysis at gene level,
we studied possible splicing variations between cancer
and benign tissues. Using DSGseq and DEXseq, we
identified 2651 genes that are differentially spliced
between prostate cancer and benign prostate tissues
(Additional file 3). This includes 55 DS kinase genes,
each of which has one differentially spliced exon
(Additional file 4).
We compared the profiles of DS and DE genes. The
overlap of two profiles has 660 genes (Fig. 2a), composing
less than 25% of the DE genes. Among the 55 DS kinase
genes, only 12 are differentially expressed between cancer
and benign samples at gene level (Fig. 2b). Most DS
kinases tend to have stable overall expression level but
have different splicing isoforms and different exon
usages. The small overlap between differential expres-
sion and differential splicing indicates that gene
expression regulation can be modulated at both gene-
level and isoform-level. Different isoform ratios and
different major isoforms can have significant func-
tional impact. The detected DE or DS kinase genes
belong to nine eukaryotic kinase families. The tyrosine
kinase (TK) family has the largest number of members
(Fig. 2c). Tyrosine kinase can phosphorylate tyrosine
amino acid on substrates specifically. TK members
function in a wide variety of processes and pathways,
from transmembrane signaling, signal transduction to
the nucleus, to cell-cycle control and transcription
factor activation [28]. TK has also been found associ-
ated with several cancers and have implications for
cancer treatment [29].
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GO and KEGG enrichment analysis show distinct functions
of DE and DS genes in prostate cancer
We performed GO and KEGG pathway enrichment ana-
lysis on the detected DE and DS genes to investigate their
biological relevance to prostate cancer. GO terms related
with cancer and prostate cancer like cell proliferation, cell
adhesion, and prostate gland development are found to be
enriched by DE genes (Additional file 5: Figure S1 and
Additional file 6). Enriched GO terms and KEGG path-
ways of DE genes include ribosome, metabolic pathways,
p53 signaling pathway, MAPK signaling pathway and
other disease-related pathways of Parkinson’s disease,
Alzheimer’s disease, prostate cancer and bladder cancer,
etc. (Additional file 5: Figure S2 and Additional file 6).
Three genes closely related to AR functions in prostate
cancer, AR, KLK3 and MAPK3, are among the detected
DE genes. In comparison, GO enrichment analysis of DS
genes shows a wide range of GO terms related to mRNA
metabolism, regulation of catalytic activity, intracellular
transport, and protein complex subunit organization etc.
(Additional file 5: Figure S3). Pathways including prote-
asome, ribosome, and spliceosome are found to be enriched
by DS genes (Additional file 6).
We also did functional enrichment analysis of the DE
and DS kinases comparing to the background of all kinases.
Interestingly, enriched GO terms of DE kinases can be
summarized as negative regulation of cellular metabolism,
enriched GO terms of DS kinases can be summarized
as positive regulation of biological process and protein
metabolic process, and both DE and DS kinases are
Table 1 Top 10 up-regulated and down-regulated genes in prostate cancer samples
Gene Symbol log2(Fold-change) p-value Role in prostate cancer based on literature and database search
Top 10 up-regulated genes
PLA2G2A 2.3884419 0 An enzyme in inflammatory process, might serve as a prognostic marker
ORM1 3.9940791 0 AR-activated gene and involved in AR pathway
TARP 2.0779529 3.13E-196 Prostate-specific protein and leads to increased
growth rate of prostate cancer cells
ORM2 3.0434879 1.52E-157
PCA3 4.0035279 1.26E-132 Highly expressed in prostate cancer tissue, a genetic
marker for prostate cancer diagnosis
SPON2 2.0706815 9.75E-121 Over expressed in prostate cancer tissues, could be
used as a biomarker
HPN 2.4321643 5.79E-49 Involved in maintenance of cell morphology and
growth of various cancer types, correlates with progression
of prostate cancer and promotes cancer progression and metastasis
STEAP4 1.9395011 4.48E-44 Module metastasis and invasion of cancer cells through
regulating focal adhesion kinase activation
MCCC2 2.0394019 4.89E-41 AR-regulated gene and strongly up-regulated in primary
prostate cancer
PDLIM5 1.8980125 2.39E-40
Top 10 down-regulated genes
SERPINA3 −1.496602 0 Associated with increased risk of prostate cancer
LTF −1.576865 0 Plays roles in several important biological processes such as




SOD2 −0.886676 1.82E-268 A tumor suppressor gene, the suppression of prostate
cancer cell growth by mediating the senescence-associated
tumor suppression
CFB −1.251122 5.91E-225
MT2A −0.516269 2.57E-188 Interact with kinase domain of protein kinase Cmu(PKCmu)
in prostate cancer
OLFM4 −1.481793 6.63E-188 Inhibit prostate cancer growth and metastasis with
nteraction of cathepsin D and SDF-1
PSCA −0.367134 1.70E-186
S100A9 −2.169907 8.63E-143
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found enriched in GO terms related to protein phosphor-
ylation (Additional file 5: Figure S4 and Additional file 7).
In the KEGG pathway analysis, detected DE kinases show
significant enrichment in cancer-related pathways (Fig. 3a,
Additional file 7), with the MAPK signaling pathway and
prostate cancer at the top of the list. The MAPK pathway
also comes at the top of the list enriched by DS kinase
genes, followed by focal adhesion etc. (Fig. 3b).
To visualize the DE and DS gene profiles in a context
of pathways, we compiled the KEGG pathway map
“Prostate Cancer” by considering the expression and
splicing difference between cancer and benign (Fig. 3c).
The gene KLK3 encodes the glyco-protein enzyme
known as prostate-specific antigen (PSA), an important
tumor marker used for diagnosis of prostate cancer in
clinical practices [24]. KLK3 is found to be both differ-
entially expressed and spliced in the pathway. The gene
HRAS was also found both differentially expressed and
spliced. HRAS belongs to the Ras oncogene family, which
encodes proteins functioning in signal transduction path-
ways. HRAS gene can produce two protein isoforms with
complementary function related to cell proliferation [30].
The differential splicing of gene HRAS may suggest the
roles of expression change at isoform level in prostate
cancer. We noted that none of the kinases that can
phosphorylate AR were differentially expressed, but four
kinases, CDK5, CDK9, PIM1 and SRC were differentially
spliced (Fig. 3d). Searching in the literature, we found that
these four DS kinases had been reported to be involved in
prostate cancer in multiple functions [31–34].
Differentially spliced kinase exons are significantly
enriched in protein kinase domain
Most of protein kinases are involved in critical cellular
activities. Splicing variability of functional region such as
ATP binding domain and kinase domain may directly
initiate or contribute to cancer progression. Alternative
splicing may regulate oncogenic kinase activity by generating
isoforms that skip kinase domain or truncate kinase domain
[9]. We investigated that whether the 55 differentially spliced
exons of DS kinases have functional impact on kinase activ-
ity by searching domains against Pfam database. We found
16 of the DS exons have domain hits in the Pfam domain
database. Among them, 9 DS exons include the protein
kinase domain (Pkinase). To verify if the functional rele-
vance of DS exons of the 55 DS exons to the kinase domain
was more significant than random chance of all alternative
splicing kinase exons, we collected all known alternative
splicing exons of 518 kinases from UCSC Genome Browser
as background and searched them in the Pfam database. In
Fig. 2 Profiles of DE and DS genes between prostate cancer and benign tissues. a Overlap of differential expression (DE) and differential splicing
(DS) genes. b Overlap of DE and DS kinase genes. c Counts of DE and DS kinase genes in protein kinase families
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total, 81 significant Pkinase domains were detected in 8671
peptide sequences translated from 1936 alternative splicing
exons of the 518 kinases. Comparing to this background, we
found that the 55 DS exons we identified are significantly
more related to protein kinase domains (p-value < 0.0007 by
Fisher’s Exact Test). Besides, we investigated that whether
the kinase domain predicted by Pfam search really existed in
the annotation database GeneCards [35]. We found that
either truncated kinase domain or total kinase domain exist
in the DS exons of the nine kinases.
These results indicated that DS exons of the DS kinases
are significantly enriched in kinase domains. Differential
splicing of these kinases may modify kinase activity
and have functional impact on phosphorylation of their
substrates in prostate cancer progression by differential
expression of isoforms including or excluding those DS
exons.
Isoform switching of CDK5 in prostate cancer and its
potential functions on AR phosphorylation
Among the 9 DS exons on kinase domain, we found that
the DS exon of CDK5 is included in one isoform and
excluded in the other. We took CDK5 as an example to
conduct further isoform-level analysis. The DS kinase
gene CDK5 has two isoforms (Fig. 4a). We found that
the two isoforms are differentially used between prostate
cancer and benign tissues (Fig. 4b). The inclusion and
exclusion of the 32 amino acid DS exon (exon 6) that
Fig. 3 Functional enrichment analysis of DE and DS kinase genes. a Enriched KEGG pathways of DE kinase genes. b Enriched KEGG pathways of
DS kinase genes. Pathways enriched in both DE and DS kinase genes are shown in light green in both plots. Those only enriched in DE kinase genes
are shown in purple in (a), and those only enriched in DS kinase genes are shown in dark green in (b). c The “Prostate Cancer” pathway in KEGG, with
detected DE and DS genes highlighted in colors. Circles represent genes, with their colors showing their fold-change between the cancer and normal
groups. Circle size indicates the NB-stat calculated by DSGseq, which represents the degree of differential splicing of the gene between the two
groups. Small molecules (triangles), cellular process (rectangles) and gene complexes (hexagon) are also shown. Colored edges indicate activation
(red), inhibition (green), phosphorylation (orange). d Expression and splicing changes of kinases that phosphorylate AR. None of the kinase genes is
differentially expressed, but CDK5, CDK9, PIM1 and SRC are differentially spliced, with node sizes representing the NB-stat in DSGseq
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defines the two isoforms, and this exon is differentially
used between the cancer and normal samples. We
refer the longer isoform with exon 6 to as Isoform1
(NM_00495 in REFSEQ), the shorter isoform as Isoform2
(NM_001164410).
Database searching revealed that the serine/threonine
protein kinase active site lies in this alternative exon of
gene CDK5 (Additional file 5: Figure S5). Isoform1 has full
length of 293 amino acids and encodes protein CDK5
while Isoform2 lacks exon 6 and encodes a 260 amino
acids protein. CDK5 is one of the cyclin-dependent kinase
(CDK) family members and plays important roles in vari-
ous cellular activities like cell differentiation and apoptosis
[36]. The function of protein encoded by Isoform2 has not
been well studied in the literature. Kim et al. reported
different subcellular localizations of two isoforms of
CDK5 which might indicate different functions [37].
CDK5 knock-down by siRNA resulted in changes of the
microtubule cytoskeleton, loss of cellular polarity and
motility in human prostate cancer DU 145 cell line [34]. It
has been reported that protein CDK5 can activate and
stabilize AR in the nucleus through Ser-81 phosphorylation
in prostate cancer cells [38]. These studies all suggested
that CDK5 may be a potential regulator in prostate cancer
progression through AR phosphorylation.
Our study showed that CDK5 is differentially spliced
between prostate cancer and benign tissues at exon 6
(Fig. 4b). We found that although CDK5 was not detected
as a DE gene at gene expression level, the relative isoform
abundances in prostate cancer and benign tissues are very
different. Isoform1 makes up more than 90% of the total
expression of CDK5 in prostate cancer but less than 40%
in benign tissues (Fig. 4c, Additional file 8). AR shows
higher expression in the prostate cancer group, with log2
fold change of ~ 1.43 comparing to the benign group.
It has been reported that protein CDK5 encoded by
Isoform1 can phosphorylate AR at its Ser-81 site and
therefore activate and stabilize AR to promote prostate
cancer cell growth in prostate cancer cell line [38].
Since the kinase domain is missed in Isoform2, this
function would be lost or weakened when Isoform2 is
dominate in normal prostate tissues. We inferred that
the higher relative expression of CDK5 Isoform1 in cancer
cells can plays an important role in AR-involved prostate
cancer progression.
We validated the CDK5 isoform expression pattern in
another RNA-Seq dataset of 21 prostate cancer and
benign cell lines [13]. This dataset contains only five
benign cell lines and the prostate cancer cell lines are
of different subtypes. We observed that the benign cell
lines still have lower Isoform1 expression (Additional
file 8), although the isoform-switching between the
prostate cancer and benign cell lines is statistically not
significant. We found that isoform1 tends to be not
Fig. 4 Differential splicing and isoform switching of kinase gene CDK5 in prostate cancer. a The transcript structure of CDK5. CDK5 is located on
Chromosome 7 and has two annotated isoforms: NM_004935 (Isoform1) and NM_001164410 (Isoform2). Isoform1 has 12 exons, and its 6th exon
is skipped in Isoform2. b Differential splicing of CDK5 illustrated by DEXSeq [17]. The relative exon usage, as measured by “fitted splicing”, was
plotted for each exon in two groups. Blue lines are for prostate benign samples and red lines are for prostate cancer samples. The panel at the
bottom shows the location of the exons, with the alternative exon highlighted in red. c Expression boxplots of the two isoforms in prostate
cancer and benign tissue samples. d Expression boxplots of the two isoforms in the androgen-independent and androgen-dependent prostate
cancer cell lines
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expressed or lowly expressed in some prostate cancer cell
lines like VCaP and LNCaP, which are androgen-dependent
prostate cancer cell lines. We applied clustering analysis on
the cell lines by their gene expression profiles, and clus-
tered them into two groups: androgen-dependent cell lines
and androgen-independent cell lines. We observed that
CDK5 has different isoform usage between androgen-
dependent and androgen-independent prostate cancer
cell lines. Isoform1 takes ~ 81% of total expression in
the androgen-independent group and ~ 28% in the
androgen-dependent group, and the proportions of
Isoform2 are ~ 19% and ~ 72%, respectively (Fig. 4d,
Additional file 8). These different isoform preferences
of CDK5 between androgen-independent or dependent
prostate cancer cell lines implies that CDK5 can modulate
AR transcriptional activity through differential splicing in
accordance with the present or absent of androgen.
Discussion
In this study, we characterized the gene expression pro-
file of prostate cancer by a systematic comparison of
RNA-Seq data of prostate cancer and benign tissues.
Quantitative analysis was applied on both the gene
expression levels and their alternative isoforms, with a
special emphasis on kinase genes. Results showed that
alternative splicing adds another layer of regulation to
gene expression by the different usage of splicing
isoforms or their different relative expressions in
cancer. Functional enrichment analysis also showed
that the differentially expressed and spliced genes are
enriched in GO terms and KEGG pathways that are
closely related to prostate cancer. Some kinase genes
that can phosphorylate AR are differentially spliced but
none of them are differentially expressed. Differentially
spliced exons of detected kinase genes are more
enriched in the protein kinase domain than other alterna-
tive splicing exons. This indicates that the differentially
spliced kinases have the potential to alter protein phos-
phorylation activity by changing abundance of isoforms
with kinase domain.
This conclusion was well illustrated by the observation
that the AR phosphorylation kinase gene CDK5 under-
goes isoform switching between prostate cancer and
benign tissues. This result was confirmed on another
RNA-Seq dataset of prostate cancer cell lines, on which
isoform ratio differences were observed between
androgen-dependent and androgen-independent pros-
tate cancer cell lines. We speculate that the isoform
usage preference of CDK5 plays an important role in
cancer cell growth by modulating AR transcriptional
activity though AR phosphorylation and AR protein
stabilization, as illustrated in the hypothetic model of
Fig. 5. The isoform ratio change of CDK5 can act as a
fine tuner of AR activity and contribute to prostate
cancer progression.
Conclusions
In summary, our study provided a transcriptome profile
of prostate cancer using RNA-Seq data with an emphasis
on differentially spliced kinase genes. It indicated alter-
native splicing has critical impact on kinase activity in
cancers. Especially, isoform switching of kinase gene
CDK5 was found in prostate cancer and benign tissues,
which suggests its regulatory role in AR phosphorylation
via alternative splicing. The work brings new under-
standing to the role of alternatively spliced kinases in
prostate cancer and provides an example on the system-
atic analysis of RNA-Seq data in cancer.
Fig. 5 A hypothetic model of the function of CDK5 isoform switching in prostate cancer. The dominance of Isoform1 over Isoform2 in cancer
increases the phosphorylation of AR, which increases its protein stabilization and activity in nucleus, and thus promote cancer-related cellular
process like cell proliferation
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